Department of Error (DOI:10.1016/S0140-6736(07)61062-9);Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?

Lancet

Volumn 370, Issue 9582, 2007, Pages 105-107

  Schmoll, Hans Joachim ^a   Sargent, Daniel ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 34447259379     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61902-3     Document Type: Erratum

References (11)

1. Saunders M., and Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 95 (2006) 131-138
2. Saltz L., Clarke S., Diaz-Rubio E., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 18S suppl (2007) 4028 (abstr).
3. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and fluorouracil/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 18S suppl (2007) 4000 (abstr).
4. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351 (2004) 317-319
5. Seymour M., Maughan T., Ledermann J., and for the FOCUS Trial Investigators* and the National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
6. Koopman M., Antonini N., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
7. Bouché O., Castaing M., Etienne P., et al. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): Preliminary results. J Clin Oncol 18S suppl (2007) 4069 (abstr).
8. Fuchs C., Marshall J., Mitchell E., et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: Updated efficacy data. J Clin Oncol 18S suppl (2007) 4027 (abstr).
9. Grothey A., Sargent D., Goldberg R., and Schmoll H. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
10. Souglakos J., Androulakis N., Syrigos K., et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94 (2006) 798-805
11. Falcone A., Ricci S., Brunetti I., et al., for the Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (2007) 1670-1676